Ketamine (IV / Esketamine) and Rheumatoid Arthritis: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Ketamine (IV / Esketamine) and Rheumatoid Arthritis: Latest Research 2026

This page summarizes the current state of scientific research on Ketamine (IV / Esketamine) in the context of Rheumatoid Arthritis as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your rheumatologist for personalized guidance.

Compound Overview

Ketamine (IV / Esketamine) (NMDA Antagonist / Anesthetic) — FDA-approved as anesthetic; esketamine (Spravato) approved for treatment-resistant depression

Mechanism of action: NMDA receptor antagonism; rapid antidepressant via AMPA activation; opioid receptor modulation; BDNF release

Current evidence level: Strong data for treatment-resistant depression; Phase II for neuropathic pain; cancer anxiety studies

2026 Research Landscape

Direct research on Ketamine (IV / Esketamine) specifically for RA remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Ketamine (IV / Esketamine) affects the biological pathways involved in Rheumatoid Arthritis progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Ketamine (IV / Esketamine)[tiab]) AND (Rheumatoid Arthritis[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Ketamine (IV / Esketamine) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Ketamine (IV / Esketamine) + RA research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in RA patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Ketamine (IV / Esketamine) for RA?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Ketamine (IV / Esketamine) Rheumatoid Arthritis' filtered to the last 2 years. The current evidence level is: Strong data for treatment-resistant depression; Phase II for neuropathic pain; cancer anxiety studies.

Are there any 2025-2026 clinical trials for Ketamine (IV / Esketamine) in RA?

Check ClinicalTrials.gov with 'Ketamine (IV / Esketamine)' as intervention and 'Rheumatoid Arthritis' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your rheumatologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Ketamine (IV / Esketamine) in RA changed recently?

The field evolves rapidly. The current evidence classification is: Strong data for treatment-resistant depression; Phase II for neuropathic pain; cancer anxiety studies. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.